Mounjaro and Ozempic warning for holiday travel insurance
Travel insurance providers are warning that the growing number of Brits turning to these breakthrough drugs for weight management could lose their cover and face huge medical bills abroad if they don't declare their usage when arranging travel insurance.
Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: https://t.co/03msJjjTU9 pic.twitter.com/tHs6lyJHc4 — We are Primary Care (@PrimaryCareNHS) June 12, 2025
Many don't want to admit they are taking the weight-loss drugs, or think that if they buy it privately online, it doesn't need to be declared.
Niraj Mamtora, director at Forum Insurance, says: 'Weight-loss medications like Ozempic are transforming lives across the UK, but too many travellers don't realise the insurance implications. If you're using these drugs, you must declare both the medication and the condition it's prescribed for.
'Failure to do so is not a minor oversight - it's a serious breach of your travel insurance contract. If you need medical help overseas and haven't declared your medication, your claim can be refused and your policy cancelled. The financial consequences can be severe.'
What happens if you don't disclose weight-loss jabs on your travel insurance?
'Non-disclosure is a gamble that's simply not worth taking," says Niraj.
"If you don't declare your medication or the underlying condition, your insurer is within their rights to refuse any claim, even if it seems unrelated.
'Many travellers only discover too late that their travel insurance claims are rejected, leaving them without support and facing potentially huge bills.
Do I Need Travel Insurance?
"With the average medical claim abroad now exceeding £1,700, and costs rising significantly with age, being properly covered is more important than ever.'
'Skinny Jab' weight loss medication is surging
According to The Pharmacist website 1.5 million UK citizens used weight-loss jabs in March 2025, and the number is believed to be growing each month.
'Recent NHS data shows that between March 2024 and February 2025, more than 83,000 unique patients in England were dispensed Ozempic, while over 344,000 people received a prescription for weight-loss medications overall in the past year," says Niraj.
'With new drugs entering the market and millions more eligible for these treatments, the number of Brits travelling with prescription weight-loss medication is set to rise further.'
Recommended reading:
What to do if you are travelling abroad while taking weight-loss medication
Declare all pre-existing medical conditions and any medications, including Ozempic, Wegovy, and Mounjaro, when purchasing travel insurance. If you are taking medication without a prescription or for off-label use, you must disclose this, as it can affect your travel cover. Carry a copy of your prescription or a doctor's letter when travelling with medication, and check the rules of your destination country regarding bringing in prescription drugs.
Remember that insurance claims related to undeclared conditions or medications can be refused, even if the issue seems unrelated.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
an hour ago
- Daily Mirror
Health-conscious Brits missing out on social occasions to stick to diets
A poll of 2,000 adults found the social events people find hard to skip when trying to eat healthily include birthday meals and takeaway nights as ice cream and brunch are among the most-missed treats Half of health-conscious Brits have skipped social occasions while they were trying to stick to strict dietary rules. A survey of 2,000 adults revealed that birthday dinners and takeaway evenings were among the social occasions people struggled to avoid when pursuing healthier habits. Meanwhile, four in ten longed to eat ice cream in the summer and a quarter missed being able to indulge in a brunch on the weekend. For others, they simply missed being able to comfort eat after a bad day. The study showed younger demographics were most inclined to decline food-centred social invitations than any other generation. According to the study, the majority of Millennials and Gen Z have turned down a gathering in the past because they were trying to commit to eating healthily. But seven in ten said skipping social occasions was the hardest part and suggested eating well shouldn't have to mean going without their favourite foods and drinks. The research was commissioned by Arla LactoFREE which recently launched a Sky Shakes pop-up in collaboration with experiential food pioneers Bompas & Parr, aiming to show that a lactose-free diet doesn't have to mean compromising on taste. Laura Butler, strategic brand manager for the company, commented: "Wellness no longer has to mean going without. It's important to find food and drink options which can be enjoyed no matter what your dietary requirements are, without having to miss out on the taste and flavour. "While it's important to many people to eat well, they also want food which feels exciting and worth sharing, which is what we hoped to deliver with the sky themed shakes made using lactose free milk and cream and crafted to be flavoursome. "Certain foods and drinks become a part of our routine and habits, be it a tea and biscuit break or an evening snack on the sofa, it's hard to stop these altogether so it's important to find alternatives." The study also revealed that treats are difficult to live without because people miss the taste and the comfort they provide. Others said the fact some foods and drinks feel like a reward (33 percent), are easy and convenient (41 percent) and are enjoyed socially (26 percent) make them tricky to give up. When it comes to eating well, half feel it's a balance between what they enjoy, and what they feel they 'should' be eating. As a result, most people said it's important for a healthy swap to still feel like a treat. Looks matter too, especially for younger generations, as 52 percent of Millennials and 47 percent of Gen Z admitted they're more likely to buy a food or drink purely based on it being ' Instagram worthy'. But people would be more inclined to see a healthy food or drink as a treat rather than a chore, if it tastes indulgent (51 percent), is full of flavour (44 percent) and feels comforting (38 percent). Laura Butler remarked: "Finding food and drink which can be enjoyed no matter what your dietary requirements are, without having to miss out of the taste and flavour, shouldn't mean having to compromise. "Everyone deserves to enjoy things which boost their moods and enable them to share the fun with others, from birthday meals to ice creams and milkshakes on a hot day."
Daily Mail
an hour ago
- Daily Mail
The unexpected Ozempic side effect that has men rushing to get their hands on weight-loss drug
A new study suggests that drugs like Ozempic may do more than lower blood sugar and aid in weight loss - they could also raise testosterone levels in men. Researchers from Saint Louis University Hospital found that men taking GLP-1 medications, including semaglutide (Ozempic) and tirzepatide (Mounjaro), saw their testosterone levels increase by 24 per cent after 18 months of treatment. Testosterone is a vital hormone responsible for male sexual development, muscle mass, bone density, red blood cell production, and fat distribution. Low testosterone is common in men with obesity or Type 2 diabetes and is linked to fatigue, reduced libido, and decreased quality of life. The new findings suggest that GLP-1 drugs may also improve reproductive health in men affected by these conditions. Researchers say the results open the door for further investigation into how anti-obesity medications can impact hormone levels and overall well-being. Lead author Dr Shellsea Portillo Canales, an endocrinology fellow at SSM Health St Louis University Hospital said: 'While it is well known that weight loss from lifestyle changes or bariatric surgery increases testosterone levels, the impact that anti-obesity medications may also have on these levels has not been widely studied. 'Our study is among the first to provide compelling evidence that low testosterone can be reversed with the use of commonly prescribed anti-obesity medications.' The researchers analyzed existing medical records of 110 adult men with obesity or Type 2 diabetes. All of the participants were being treated with semaglutide (Ozempic or Wegovy), dulaglutide (Trulicity) or tirzepatide (Zepbound) for one and a half years. All three drugs are known to mimic the effects of GLP-1, a natural hormone in the body that regulates blood sugar and appetite, often leading to lower blood sugar and weight loss. None of the men were on testosterone or hormonal therapy before or during the experiment. Some risks of testosterone therapy include worsening sleep apnea, acne, enlarging the prostate or breasts, increasing the growth of prostate cancer, reducing sperm counts, causing the testicles to shrink and increasing the risk of clots, according to the Mayo Clinic. The researchers measured the participants' total and free testosterone levels before and during their treatment. Results showed that the participants experienced 10 per cent of weight loss and saw their testosterone levels rise from 53 per cent to 77 per cent. The scientists are yet to discover how GLP-1 drugs can increase testosterone. However, previous research has shown that excess fat can force the body to convert testosterone into estrogen, a female hormone. But when obese individuals start to lose weight, they reduce their body fat stores, which can improve insulin sensitivity in the body and reduce overall inflammation. Both decreased inflammation and weight loss can help the body produce more testosterone and prevent the conversion of the male hormone into estrogen. Talking about the preliminary results, Dr Portillo Canales said: 'Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels. 'Doctors and their patients can now consider this class of medications not only for the treatment of obesity and to control blood sugar, but also to benefit men's reproductive health.' But despite clear results, the study authors noted that further research is needed to establish a clear link between the drugs and an increase in testosterone. However, seeing how beneficial the discovery is, Dr Fatima Cody Stanford, an obesity medicine physician scientist at Massachusetts General Hospital who was not involved in the study, told NBC News: 'The findings from this study highlight an important intersection between metabolic health and hormonal balance. 'This dual benefit underscores the potential of these medications to enhance overall health outcomes, including reproductive health, in this population.' Average testosterone levels in men are between 300 to 1,000 nanograms per deciliter. Testosterone tends to decline gradually with age, starting around the late 30s to early 40s. By the age of 75, the average male testosterone level drops to about 65 per cent of the average level seen in young adults, Dr Portillo Canales said. The findings were presented today at ENDO 2025, the Endocrine Society's meeting in San Francisco.
Reuters
2 hours ago
- Reuters
As weight-loss spending soars, US employers plan to pare health benefits
NEW YORK, July 16 (Reuters) - More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by consulting firm Mercer on Wednesday. Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers. That is up from 45% of large employers who said they would increase cost-sharing for 2025. Concern over the cost of GLP-1 weight-loss drugs like Novo Nordisk's ( opens new tab Wegovy has surged, with 77% of employers naming them a top issue, the consultancy said. "More clients are saying ... 'I don't know how much longer we can sustain covering these medications'," said Alysha Fluno, a pharmacy innovation leader at Mercer, in an interview. While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some employers facing big cost increases in 2026 may feel this coverage is out of reach," Fluno said. Greater competition in the weight-loss drug market in coming years will give pharmacy benefit managers more negotiating power with drugmakers and drive meaningful cost reductions, said Fluno. Novo's Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound are listed at $1086 and $1059, respectively, but many patients pay less through their health plans. Prescription drug costs jumped 8% last year, according to the survey. Mercer has forecast a 5.8% rise in overall health benefit costs for 2025. Employers are also eyeing alternatives to traditional pharmacy benefit managers (PBMs), according to Mercer. PBMs such as CVS Caremark, Cigna's Express Scripts and UnitedHealthcare's Optum Rx act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of medications that are covered by insurance, and reimburse pharmacies for prescriptions. Drugmakers say they take an undisclosed cut of the discounts they receive rather than sharing them with patients and payers. Regulatory scrutiny and calls for transparency are fueling interest in new models and emerging PBMs, with 34% of employers considering a switch. The survey found 40% of employers are considering alternative contracting models for their prescription medicine benefits, such as those that price drugs based on the wholesale price that retail pharmacies pay for them. Regulators have criticized the three largest pharmacy benefit managers for steering patients toward more expensive drugs and inflating prices to generate revenue gains, an accusation that the industry denies. California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday that Caremark would replace UnitedHealth's Optum Rx as the fund's PBM in 2026. CalPERS said its five-year contract with Caremark requires the PBM to boost transparency and oversight.
